GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Misonix Inc (NAS:MSON) » Definitions » Forward PE Ratio

Misonix (Misonix) Forward PE Ratio : 0.00 (As of May. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Misonix Forward PE Ratio?

Misonix's Forward PE Ratio for today is 0.00.

Misonix's PE Ratio without NRI for today is 0.00.

Misonix's PE Ratio for today is 0.00.


Misonix Forward PE Ratio Historical Data

The historical data trend for Misonix's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Misonix Forward PE Ratio Chart

Misonix Annual Data
Trend
Forward PE Ratio

Misonix Quarterly Data
Forward PE Ratio

Competitive Comparison of Misonix's Forward PE Ratio

For the Medical Devices subindustry, Misonix's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Misonix's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Misonix's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Misonix's Forward PE Ratio falls into.



Misonix Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Misonix  (NAS:MSON) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Misonix Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Misonix's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Misonix (Misonix) Business Description

Traded in Other Exchanges
N/A
Address
1938 New Highway, Farmingdale, NY, USA, 11735
Misonix Inc is a medical devices company. It designs, manufactures, markets, and sells invasive surgical ultrasonic medical devices. The company's products enhance clinical outcomes and provide value to the overall healthcare system. It has developed products such as BoneScalpel, NeXus, Sequel, SonaStar, SonicOne, Theragenesis, TheraSkin, and Therion. These products are used for precise bone sculpting, removal of soft and hard tumors, tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgery. The company generates revenue from various regions that include the United States, the United Kingdom, the European Economic Area, Asia and the Asia Pacific, and South America.
Executives
Paul A Laviolette director ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sharon W Klugewicz officer: Chief Operating Officer 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Thomas M Patton director C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
Joseph P Dwyer officer: Chief Financial Officer 3 CORDWOOD COURT, E. NORTHPORT NY 11731
Gwendolyn A Watanabe director C/O SARATOGA VENTURES, 210 ALMENDRA AVENUE, LOS GATOS CA 95030
Linwood A. Staub officer: Sr. VP Wound 8023 VANTAGE DRIVE SAN ANTONIO TX 78230
Stavros G. Vizirgianakis director, officer: CEO 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Robert S Ludecker officer: SVP Sales - Surgical 4 WILDBRIAR COURT MOUNT SINAI NY 11766
Allan Richard Staley officer: President C/O SOLSYS MEDICAL, LLC 600 THIMBLE SHOALS BLVD., SUITE 200 NEWPORT NEWS VA 23606
Michael Koby director C/O 1315 CAPITAL 2929 WALNUT STREET, SUITE 1240 PHILADELPHIA PA 19104
1315 Capital Management, Llc 10 percent owner 2929 WALNUT STREET SUITE 1240 PHILADELPHIA PA 19104
Sv Life Sciences Fund Vi (gp), L.p. 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Svlsf Vi, Llc 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sv Life Sciences Fund Vi Strategic Partners, L.p. 10 percent owner C/O SV LIFE SCIENCES ADVISERS, LLC, ONE BOSTON PLACE, SUITE 3900, BOSTON MA 02108
1315 Capital, L.p. 10 percent owner 3020 MARKET STREET, SUITE 104 PHILADELPHIA PA 19104